To facilitate attainment of a sexually functional erection in males with erectile dysfunction
Insufficient evidence to support the superiority of one selective PDE type 5 inhibitor over another
Symptomatic management of PAH (WHO group 1 pulmonary hypertension) to improve exercise capacity and delay clinical worsening.
Use with caution in the treatment of ED in patients with a recent (within 6 months) MI, stroke, or life-threatening arrhythmia; in patients with resting hypotension (BP <90/50 mm Hg) or hypertension (BP >170/110 mm Hg); or in patients with cardiac failure or CAD causing unstable angina.
Symptomatic hypotension may occur in patients receiving concomitant α-adrenergic blocking agents; hypotension may be severe or fatal in patients receiving an organic nitrate or nitrite concomitantly.
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.